Thomas Hawthorne

3.1k total citations
40 papers, 1.2k citations indexed

About

Thomas Hawthorne is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Thomas Hawthorne has authored 40 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 12 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Immunology. Recurrent topics in Thomas Hawthorne's work include CAR-T cell therapy research (9 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Thomas Hawthorne is often cited by papers focused on CAR-T cell therapy research (9 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Thomas Hawthorne collaborates with scholars based in United States, Germany and Switzerland. Thomas Hawthorne's co-authors include Michael Yellin, Elizabeth Crowley, Tibor Keler, Thomas A. Davis, Matthew H. Taylor, Diego Alvarado, Branimir I. Šikić, Stephen M. Ansell, Richard Görlick and Víctor M. Villalobos and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Thomas Hawthorne

39 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Hawthorne United States 20 660 421 274 243 226 40 1.2k
Donald Wong United States 16 731 1.1× 553 1.3× 316 1.2× 107 0.4× 65 0.3× 28 1.1k
Sandra Salvi Italy 23 707 1.1× 523 1.2× 473 1.7× 208 0.9× 118 0.5× 44 1.5k
Hidekazu Segawa Japan 15 458 0.7× 106 0.3× 317 1.2× 175 0.7× 180 0.8× 20 985
Philippe Quittet France 22 501 0.8× 456 1.1× 416 1.5× 85 0.3× 139 0.6× 49 1.6k
Aniruddha Choudhury Sweden 20 909 1.4× 1.2k 2.7× 460 1.7× 111 0.5× 185 0.8× 38 1.7k
Mischa Houtkamp Netherlands 10 376 0.6× 294 0.7× 207 0.8× 96 0.4× 274 1.2× 16 782
Kathrin Schwager Switzerland 14 482 0.7× 375 0.9× 301 1.1× 62 0.3× 487 2.2× 17 1.0k
Michael A. Cannarile Switzerland 16 770 1.2× 1.3k 3.1× 435 1.6× 183 0.8× 52 0.2× 27 1.9k
Carlos de Andrea Spain 10 658 1.0× 519 1.2× 231 0.8× 234 1.0× 41 0.2× 23 1.1k
Mark B. Meads United States 12 753 1.1× 307 0.7× 771 2.8× 129 0.5× 71 0.3× 36 1.6k

Countries citing papers authored by Thomas Hawthorne

Since Specialization
Citations

This map shows the geographic impact of Thomas Hawthorne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Hawthorne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Hawthorne more than expected).

Fields of papers citing papers by Thomas Hawthorne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Hawthorne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Hawthorne. The network helps show where Thomas Hawthorne may publish in the future.

Co-authorship network of co-authors of Thomas Hawthorne

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Hawthorne. A scholar is included among the top collaborators of Thomas Hawthorne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Hawthorne. Thomas Hawthorne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maurer, Marcus, Martin Metz, John Anderson, et al.. (2025). Anti‐ KIT Barzolvolimab for Chronic Spontaneous Urticaria. Allergy. 80(8). 2178–2186. 6 indexed citations
2.
Metz, Martin, Sonja Ständer, Leigh Nattkemper, et al.. (2025). Safety and efficacy of barzolvolimab, an anti–KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single dose study. Journal of the American Academy of Dermatology. 93(6). 1596–1599. 1 indexed citations
3.
Alvarado, Diego, Marcus Maurer, Richard Gedrich, et al.. (2022). Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study. Allergy. 77(8). 2393–2403. 62 indexed citations
4.
Terhorst‐Molawi, Dorothea, Tomasz Hawro, Lea Kiefer, et al.. (2022). Anti‐KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 78(5). 1269–1279. 81 indexed citations
5.
Vahdat, Linda T., Peter Schmid, Andres Forero‐Torres, et al.. (2021). Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study. npj Breast Cancer. 7(1). 57–57. 39 indexed citations
6.
Ansell, Stephen M., Ian W. Flinn, Matthew H. Taylor, et al.. (2020). Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. Blood Advances. 4(9). 1917–1926. 52 indexed citations
7.
McGregor, Bradley A., Michael S. Gordon, Ronan Flippot, et al.. (2020). Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Investigational New Drugs. 38(6). 1807–1814. 24 indexed citations
8.
Duvvuri, Umamaheswar, Jonathan George, Seungwon Kim, et al.. (2019). Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. Clinical Cancer Research. 25(19). 5752–5758. 26 indexed citations
9.
10.
Burris, Howard A., Jeffrey R. Infante, Stephen M. Ansell, et al.. (2017). Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 35(18). 2028–2036. 108 indexed citations
11.
Rose, April A. N., Matthew G. Annis, Dennie T. Frederick, et al.. (2016). MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. Clinical Cancer Research. 22(24). 6088–6098. 40 indexed citations
12.
Yardley, Denise A., Robert Weaver, Michelle Melisko, et al.. (2015). EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer. Journal of Clinical Oncology. 33(14). 1609–1619. 145 indexed citations
13.
Anandasabapathy, Niroshana, Gaëlle Breton, Arlene Hurley, et al.. (2015). Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplantation. 50(7). 924–930. 81 indexed citations
14.
Reardon, David A., James M. Schuster, David Tran, et al.. (2015). ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.. Journal of Clinical Oncology. 33(15_suppl). 2009–2009. 59 indexed citations
15.
Ansell, Stephen M., Donald W. Northfelt, Ian W. Flinn, et al.. (2014). Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies.. Journal of Clinical Oncology. 32(15_suppl). 3024–3024. 20 indexed citations
16.
Infante, Jeffrey R., Howard A. Burris, Stephen M. Ansell, et al.. (2014). Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 3027–3027. 9 indexed citations
17.
Hawthorne, Thomas, Loïc Giot, Lauren E. Blake, et al.. (2008). A Phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. International Journal of Clinical Pharmacology and Therapeutics. 46(5). 236–244. 25 indexed citations
18.
Molife, R., James Lee, Daniel Petrylak, et al.. (2007). A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 6. 2 indexed citations
19.
Sznol, Mario, David S. Sanders, A. Y. Bedikian, et al.. (2007). A phase I and pharmacokinetic study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III /IV melanoma. Molecular Cancer Therapeutics. 6. 3 indexed citations
20.
Hawthorne, Thomas, et al.. (1994). Isolation and characterization of recombinant annexin V expressed in Saccharomyces cerevisiae. Journal of Biotechnology. 36(2). 129–143. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donald Wong Breakdown of academic impact, for papers by Sandra Salvi Breakdown of academic impact, for papers by Hidekazu Segawa Breakdown of academic impact, for papers by Philippe Quittet Breakdown of academic impact, for papers by Aniruddha Choudhury Breakdown of academic impact, for papers by Mischa Houtkamp Breakdown of academic impact, for papers by Kathrin Schwager Breakdown of academic impact, for papers by Michael A. Cannarile Breakdown of academic impact, for papers by Carlos de Andrea Breakdown of academic impact, for papers by Mark B. Meads
Rankless by CCL
2026